tirzepatide approved for osa The FDA has just Zepbound (tirzepatide), the first medication designed to treat both obstructive sleep apnoea (OSA) and obesity simultaneously. In clinical trials, Zepbound helped reduce breathing disruptions by 50% and What clinicians should know about

These results suggest that SYNCRIP regulates ferroptosis indirectly through the SIRT1/NRF2/xCT axis rather than by directly modulating GPX4

599 Ndfip1 overexpression may restore mitochondrial dysfunction in PD mice by regulating voltage-dependent anion-selective channels

Whilst routine bone density monitoring is not currently recommended for all patients on GLP-1 receptor agonists, certain circumstances warrant medical review

Watch this space for more developments

Ishika and Khunger are with Department of Dermatology and Sexually Transmitted Diseases at Vardhman Mahavir Medical College and Safdarjung Hospital in Delhi, India